The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome

Elham Rahmani, Mehri Jamilian, Mansooreh Samimi, Maryam Zarezade Mehrizi, Esmat Aghadavod, Elmira Akbari, Omid Reza Tamtaji & Zatollah Asemi

To cite this article: Elham Rahmani, Mehri Jamilian, Mansooreh Samimi, Maryam Zarezade Mehrizi, Esmat Aghadavod, Elmira Akbari, Omid Reza Tamtaji & Zatollah Asemi (2017): The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome, Gynecological Endocrinology, DOI: 10.1080/09513590.2017.1381680

To link to this article: http://dx.doi.org/10.1080/09513590.2017.1381680
The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome

Elham Rahmani, Mehri Jamilian, Mansooreh Samimi, Maryam Zarezade Mehrizi, Esmat Aghadavod, Elmira Akbarnia, Omid Reza Tamtajie and Zatollah Asemi

ABSTRACT

Objective: This research was conducted to assess the effects of coenzyme Q10 (CoQ10) intake on gene expression related to insulin, lipid and inflammation in subjects with polycystic ovary syndrome (PCOS).

Methods: This randomized double-blind, placebo-controlled trial was conducted on 40 subjects diagnosed with PCOS. Subjects were randomly allocated into two groups to intake either 100 mg CoQ10 (n=20) or placebo (n=20) per day for 12 weeks. Gene expression related to insulin, lipid and inflammation were quantified in blood samples of PCOS women with RT-PCR method.

Results: Results of RT-PCR shown that compared with the placebo, CoQ10 intake downregulated gene expression of oxidized low-density lipoprotein receptor 1 (LDLR) (p < 0.001) and upregulated gene expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) (p = 0.01) in peripheral blood mononuclear cells of subjects with PCOS. In addition, compared to the placebo group, CoQ10 supplementation downregulated gene expression of interleukin-1 (IL-1) (p = 0.03), interleukin-8 (IL-8) (p = 0.001) and tumor necrosis factor alpha (TNF-α) (p < 0.001) in peripheral blood mononuclear cells of subjects with PCOS.

Conclusions: Overall, CoQ10 intake for 12 weeks in PCOS women significantly improved gene expression of LDLR, PPAR-γ, IL-1, IL-8 and TNF-α.

Introduction

Polycystic ovary syndrome (PCOS) is a prevalent heterogeneous complication related to disorders of reproductive, metabolic and endocrine function [1]. The prevalence of PCOS among reproductive-aged women was reported 6–25%, depending on defined criteria [2]. Previous evidences show that PCOS is associated with hyperandrogenism and metabolic variations including insulin resistance and lipid disorders [3]. In addition, a relation has been observed between pro-inflammatory genotypes and PCOS, linked to polymorphism of genes coding for tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) [4].

Coenzyme Q10 (CoQ10) is a nutrient that plays an important function in the production of cellular energy as well as acts in scavenging free radicals and inhibiting lipid and protein oxidation as an antioxidant [5]. Previously, beneficial effects of CoQ10 on gene expression related to insulin, lipid and inflammation among subjects without PCOS have evaluated. Tarry-Adkins et al. [6] found that postweaning dietary intake of recuperated animals with CoQ10 prevented the programed reduction in insulin receptorsubstrate-1 and p110-β and the programed increased in IL-6. In addition, another study was seen that CoQ10 administration at a dosage of 20 mg/kg increased insulin sensitivity and had antidiabetic properties via increasing activity of phos- phatidylinositol kinase (P13K) in rats fed a high-fat, high-fructose diet [7]. Mediterranean diet with CoQ10 also modified gene expression of pro-inflammatory markers among elderly men and women for four weeks [8].

This evidence might support the importance of CoQ10 administration in women with PCOS. According to the best of our knowledge, data on the effects of CoQ10 intake on gene expression related to insulin, lipid and inflammation in subjects with PCOS are limited. The objective of our study was to determine the effects of CoQ10 on gene expression related to insulin, lipid and inflammation in subjects with PCOS.

Subjects and methods

Trial design and participants

This randomized double-blind placebo-controlled clinical trial, registered in the Iranian website for registration of clinical trials (http://www.irct.ir: IRCT201605225623N80), was done among 40 subjects with PCOS diagnosed according to the Rotterdam criteria [9] aged 18–40 years old who referred to the Kosar Clinic in Arak and the Persian Gulf Martyrs Hospital in Bushehr, Iran, between May 2016 and September 2016. We excluded pregnant, elevated levels of prolactin, endocrine diseases and no hormonal treatments in the previous 6 months in the study. This research was approved by the ethics committee of Arak University of Medical Sciences (AUMS) and informed consent form was taken...
from all subjects. All subjects were matched according to age, phenotypes of PCOS and BMI at the study baseline. Subjects were then randomly divided into two groups to receive either CoQ10 \((n = 20)\) or placebo \((n = 20)\) for 12 weeks. CoQ10 and its placebos (cellulose) were provided by Nature Made Pharmaceutical Company (New York, NY, USA) and Barij Essence Pharmaceutical Company (Kashan, Iran), respectively.

**Treatment adherence**

To evaluate the compliance, we counted the remaining supplements. To increase compliance, all women received short messages every day to remind them about taking the capsules.

**Assessment of anthropometric measures**

Weight and height of participants were determined in an overnight fasting status using a standard scale (Seca, Hamburg, Germany) at the beginning of the study and after 12-weeks intervention. BMI was calculated as weight in kg divided by height in meters squared.

**Assessment of outcomes**

In our study, gene expression of peroxisome proliferator-activated receptor gamma (PPAR-\(\gamma\)) and glucose transporter 1 (GLUT-1) were considered as the primary outcome and gene expression of lipoprotein(a) \([Lp(a)]\), oxidized low-density lipoprotein receptor 1 (LDLR), interleukin-1 (IL-1), interleukin-8 (IL-8), tumor necrosis factor alpha (TNF-\(\alpha\)) and transforming growth factor beta (TGF-\(\beta\)) were considered as the secondary outcomes.

**Isolation of lymphocyte cells**

At baseline and endpoint of the intervention, 10 ml samples of venous blood were taken after overnight fasting at Arak reference laboratory. Then, lymphocyte cells were extracted from blood samples of subjects with PCOS by the use of a 50\% percoll (Sigma-Aldrich, Dorset, UK). Samples were taken for cell count and viability testing by trypan blue, RNA and DNA extraction.

**RNA extraction and real-time PCR**

To RNA extraction, we used the RNX-plus kit (Cinnacolon, Tehran, Iran). RNA suspension was frozen in \(-20^\circ C\) until cDNA making. Following extraction of the total RNAs from each sample, RNA quantification were performed by UV spectrophotometer. Each samples OD 260/280 ratio between 1.7 and 2.1 was intended that shows no contamination with both protein and DNA [10]. The isolated RNA was reverse transcribed to cDNA library using moloney murine leukemia virus (MMLV) reverse transcriptase (RT). Gene expression of PPAR-\(\gamma\), GLUT-1, Lp(a) and LDLR were evaluated by quantitative RT-PCR, using the LightCycler technology (Roche Diagnostics, Rotkreuz, Switzerland) with SYBR green detection and Amplicon Kit (Table 1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were used as housekeeping gene. To design primers, Primer Express Software (Applied Biosystems, Foster City, CA, USA) and Beacon designer software (Takaposizt, Tehran, Iran) were used. Relative transcription levels were calculated by the method of Pfaffi or \(2^{-\Delta\Delta CT}\).

**Randomization**

Randomization assignment was done using computer-generated random numbers as blindness by a trained staff at the gynecology clinic.

**Statistical methods**

To establish normal data distribution, we used the Kolmogrov–Smirnov test. To establish differences in anthropometric measures as well as in macro- and micro-nutrient dietary intakes between the two groups, we applied independent samples \(t\)-test. To determine the effects of CoQ10 supplementation on gene expression involved in lipid, insulin and inflammation signaling pathway, we used independent samples \(t\)-test. The \(p < 0.05\) were considered statistically significant. All data entry and

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer Product size (bp)</th>
<th>Annealing temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>F: AAGCTCATTTCTCGGTATGACACAG 126</td>
<td>61.3</td>
</tr>
<tr>
<td></td>
<td>R: TCTCCTCTGGCCTGGTCGGG</td>
<td></td>
</tr>
<tr>
<td>PPAR-(\gamma)</td>
<td>F: ATGACAGACCTCCAGACAAGTAGG 210</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>R: AATTGGCTGGATGGCTCAAGC</td>
<td></td>
</tr>
<tr>
<td>GLUT-1</td>
<td>F: TATCTGAGCATGGGCGCAT      238</td>
<td>62.1</td>
</tr>
<tr>
<td></td>
<td>R: AAGACATAGGGACACACACAG</td>
<td></td>
</tr>
<tr>
<td>Lp(a)</td>
<td>F: GACACAGCAAGTTCCATTCA     200</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>R: ACACCCCCCTACAATGCTTC</td>
<td></td>
</tr>
<tr>
<td>LDLR</td>
<td>F: ACTTACGAGACAGACACAG       223</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>R: GGGCAACACATCCGATGTG</td>
<td></td>
</tr>
<tr>
<td>IL-1</td>
<td>F: GCTTCCTCCGGGCTCGG        174</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>R: AGGGGAGTGAGGAAGAG</td>
<td></td>
</tr>
<tr>
<td>IL-8</td>
<td>F: GCGAGGGCTTGGGAGAAGT      150</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>R: ACCCTACAACAGACCCCACAC</td>
<td></td>
</tr>
<tr>
<td>TNF-(\alpha)</td>
<td>F: GTCAACCTCTCTGTCGGCAT    188</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>R: CCAAAGTACACTGCCCAGC</td>
<td></td>
</tr>
<tr>
<td>TGF-(\beta)</td>
<td>F: TTGACCTTTTCCGGTGG       227</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>R: CGAGTCTCGGGGAAAGAATCT</td>
<td></td>
</tr>
</tbody>
</table>

GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLUT-1: glucose transporter 1; IL-1: interleukin-1; IL-8: interleukin-8; Lp(a): lipoprotein(a); LDLR: oxidized low-density lipoprotein receptor 1; PPAR-\(\gamma\): peroxisome proliferator-activated receptor gamma; TNF-\(\alpha\): tumor necrosis factor alpha; TGF-\(\beta\): transforming growth factor beta.
statistical analyzes were conducted using the Statistical Package for Social Science version 18 (SPSS Inc., Chicago, IL, USA).

Results
At baseline, we were invited 55 women; however, 15 women were excluded from the study because of not meeting inclusion criteria. In the current study, 40 women [placebo (n = 20) and CoQ10 (n = 20)] completed the trial (Figure 1).

Mean age, height, and weight and BMI at baseline and end-of-trial were not statistically different between the two groups (Table 2).

Results of RT-PCR indicated that compared with the placebo, CoQ10 intake downregulated gene expression of LDLR (p < 0.001), but did not affect gene expression of LP(a) in peripheral blood mononuclear cells of subjects with PCOS (Figure 2).

We found that CoQ10 intake, compared with the placebo, upregulated gene expression of PPAR-γ (p = 0.01), but unchanged gene expression of GLUT-1 in peripheral blood mononuclear cells of subjects with PCOS (Figure 3).

Compared with the placebo, CoQ10 intake downregulated gene expression of IL-1 (p = 0.03), IL-8 (p = 0.001) and TNF-α (p < 0.001), but did not influence gene expression of TGF-β in peripheral blood mononuclear cells of subjects with PCOS (Figure 4).

Discussion
However, in another study, we have previously shown beneficial effects of CoQ10 on insulin metabolism and some lipid profiles in patients with PCOS [11], to our knowledge, this trial is the first evaluating effects of CoQ10 on gene expression related to insulin, lipid and inflammation among women with PCOS. We demonstrated that CoQ10 intake for 12 weeks among subjects with PCOS had beneficial effects on few gene expression related to insulin, lipid and inflammation.

Subjects with PCOS are susceptible to some metabolic disorders and inflammation [12,13]. We found that taking CoQ10 for 12 weeks in subjects with PCOS downregulated LDLR expression, but did not affect Lp(a) expression. Tsai et al. [14] seen that CoQ10 rescued dephosphorylation of AMP-activated protein kinase (AMPK) caused by Ox-LDL. In addition, CoQ10 attenuated the Ox-LDL-induced generation of reactive oxygen species (ROS) [15]. Prior genetic and epidemiologic studies have shown that Ox-LDL and Lp(a) are risk factors of atherosclerotic diseases such as CHD [16–18]. CoQ10 intake mat decrease Ox-LDL-induced endothelial oxidative injuries by the modulation of LOX-1-mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway [14].

This research demonstrated that CoQ10 supplementation for 12 weeks in subjects with PCOS upregulated PPAR-γ expression, but unchanged GLUT-1 expression. However, data on the effects of CoQ10 intake on gene expression of PPAR-γ and GLUT-1 are scarce; few studies have evaluated the effects of CoQ10 on gene expression related to insulin. Lee et al. [19] found that CoQ10 increased gene expression of PPAR-γ at both the mRNA and protein levels in 3T3-L1preadipocytes. In addition, supplementation with CoQ10 induced gene expression of PPAR-γ in SAMP1 mice [20]. In another study, CoQ10 supplementation increased p110β protein expression both liver and skeletal muscle [6]. This is consistent with prior studies indicating that administration of a much higher dose of CoQ10 (20 mg/kg) affects insulin sensitivity and had antidiabetic properties via increasing the activity of phosphatidylinositol kinase (PI-3Ks) in rats fed with a high-fat, high-fructose diet [7]. PPAR-γ is primarily present in adipocytes, which plays an important function in glucose and insulin metabolism [21]. CoQ10 intake may induce PPAR-γ expression through the calcium-mediated AMPK signal pathway and suppressing differentiation-induced adipogenesis [19].

Assessed for eligibility (n=55)  
Excluded (n=15)  
- Not meeting inclusion criteria (n=10)  
- Not living in Arak (n=5)  

Randomized (n=40)  

Allocated to placebo (n=20)  
Lost to follow-up (n=0)  
Analyzed (n=20)  

Allocated to intervention (n=20)  
Lost to follow-up (n=0)  
Analyzed (n=20)  

Figure 1. Summary of patient flow diagram.
Figure 2. Effect of 12-week supplementation with CoQ10 or placebo on expression ratio of Ox-LDL and Lp(a) gene in blood mononuclear cells of PCOS women.

Figure 3. Effect of 12-week supplementation with CoQ10 or placebo on expression ratio of PPAR-γ and GLUT-1 gene in blood mononuclear cells of PCOS women.

Figure 4. Effect of 12-week supplementation with CoQ10 or placebo on expression ratio of IL-1, IL-8, TNF-α, and TGF-β gene in blood mononuclear cells of PCOS women.

Table 2. General characteristics of study participants.

<table>
<thead>
<tr>
<th></th>
<th>Placebo group (n = 20)</th>
<th>CoQ10 group (n = 20)</th>
<th>p (^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>24.7 ± 5.3</td>
<td>24.9 ± 3.7</td>
<td>0.91</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>162.5 ± 6.6</td>
<td>160.8 ± 7.8</td>
<td>0.47</td>
</tr>
<tr>
<td>Weight at baseline (kg)</td>
<td>76.5 ± 17.1</td>
<td>71.6 ± 11.1</td>
<td>0.29</td>
</tr>
<tr>
<td>Weight at end-of-trial (kg)</td>
<td>76.1 ± 17.7</td>
<td>71.9 ± 10.8</td>
<td>0.36</td>
</tr>
<tr>
<td>Weight change (kg)</td>
<td>−0.4 ± 1.0</td>
<td>0.3 ± 5.7</td>
<td>0.63</td>
</tr>
<tr>
<td>BMI at baseline (kg/m²)</td>
<td>28.9 ± 6.6</td>
<td>27.7 ± 3.6</td>
<td>0.44</td>
</tr>
<tr>
<td>BMI at end-of-trial (kg/m²)</td>
<td>28.8 ± 6.7</td>
<td>27.8 ± 3.6</td>
<td>0.54</td>
</tr>
<tr>
<td>BMI change (kg/m²)</td>
<td>−0.1 ± 0.3</td>
<td>0.1 ± 2.1</td>
<td>0.61</td>
</tr>
</tbody>
</table>

Data are means ± SDs.

\(^a\)Obtained from independent t-test.
We found that taking CoQ10 for 12 weeks in subjects with PCOS downregulated gene expression of IL-1, IL-8 and TNF-α compared with the placebo, but did not affect gene expression of TGF-β. Yoneda et al. [22] demonstrated that CoQ10 reduced gene expression of interleukin-1β, TNF-α and nuclear factor-κB (NF-κB) in rats after 8 days. In another study, CoQ10 supplementation significantly reduced the IL-6 protein and TGF-β1 and Lep mRNA levels [6]. In addition, our study was in agreement with findings in cardiac tissue [23], and CoQ10 is known to have anti-inflammatory properties in mouse liver [24] and human plasma [25]. Also, gene expression of TNF-α were significantly decreased following CoQ10 intake in an experimental model of multiple sclerosis for three weeks [26]. Increased inflammatory cytokines would result in the development of insulin resistance via the inhibition of insulin signaling through activation of the inhibitory-κB kinase-β and c-Jun N-terminal kinase pathways [27]. Moreover, inflammation in subjects with PCOS render them at an increased risk for the development of atherosclerosis and infertility [28]. Due to its antioxidant and radical scavenging activity, CoQ10 can reduce ROS production and free radicals, which in turn could affect gene expression of TNF-α via the NF-κB pathway [29].

The current study had few limitations. We did not evaluate CoQ10 levels at baseline and at the end-of-trial. Furthermore, in the current study, we considered PPAR-γ and GLUT-1 as gene expressions involved in the insulin signaling pathway. However, GLUT-1 is not directly influenced by insulin, it is not surprising whether we did not observe any variation of GLUT-1 gene expression following the supplementation of CoQ10. We agree that other insulin-dependent transporters such as GLUT-4 or other post-receptor steps including insulin receptor substrate 1 or-2 and PKB are more important than such as GLUT-1 gene expression following the supplementation of CoQ10. Overall, CoQ10 supplementation for 12 weeks in PCOS women significantly improved gene expression of LDLR, PPAR-γ, IL-1, IL-8 and TNF-α, but did not affect gene expression of Lp(a), GLUT-1 and TGF-β.

Acknowledgements

This study was founded by a grant from the Vice-chancellor for Research, BPUMS and AUMS, and Iran. The authors would like to thank the staff of Kosar Clinic (Arak, Iran) for their assistance on this project.

Disclosure statement

No potential conflict of interest was reported by the authors.

References


